HomeAbout UsContact Us1-800-688-2421
BioWorld
Advanced Search

User ID

Password

Forgot password

Remember my login



New User ?

Products & Services
BIOWORLD TODAY
BIOWORLD FINANCIAL WATCH
BIOWORLD INTERNATIONAL
BIOTECH RESOURCES
MEDTECH RESOURCES
BIOWORLD INNOVATIONS REPORT 2008
BIOWORLD GENOMICS REPORT 2008
BIOWORLD EXPANSION AND RELOCATION GUIDE 2008
BIOWORLD PERSPECTIVES
AUDIO CONFERENCES
MEDICAL DEVICE DAILY
Untitled Document
BioWorld Stock Index
For the week ending 8/22/08
-2.89

AMEX Biotech Index
Close 8/27/08
823.40  -15.06

NASDAQ Biotech Index
Close 8/27/08
883.99  -6.59
Today's Issue of BioWorld Today

BioWorld Wire, powered by PR Newswire
Biotech news | Pharma news

Thursday, August 28, 2008

Today's Headlines

Cell Genesys Falls 70% as Patient Deaths Derail GVAX Phase III

In yet another setback for cancer vaccines, Cell Genesys Inc. terminated one of its two Phase III trials with prostate cancer vaccine GVAX. (BioWorld Today)

Advances and Challenges in RNAi, Stem Cells and Synthetic Biology

A new market report from BioWorld Today appraises the state and potential of the genomics technologies market allowing you to see where the trends are taking us for 2009. View more details here to get insight into these next-generation technologies.

86 Years After Insulin, Type I Diabetes Drugs Promise More

In the early part of the 20th century, before the Depression and World War II, dozens of children lay comatose in hospital wards where hopeless families gathered awaiting their inevitable deaths. This was not cancer before chemotherapy, or tuberculosis before antibiotics. This was Type I diabetes before insulin. (BioWorld Financial Watch)

Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma

Novosom AG in-licensed from Isis Pharmaceuticals Inc. the rights to antisense inhibitors that target CD40 mRNA for several indications, including Crohn's disease, rheumatoid arthritis and organ transplant rejection. (BioWorld International)



Biofuels Are Driving Green Biotech to New Market Value — Biofuels has placed itself at the forefront of many government initiatives concerning biotechnology, transportation, oil, and energy. This new in-depth report provides forecasts well beyond current standard projections and identifies the growth potential through a variety of data. View a complete index of this report here.

BioWorld Home   |   About BioWorld   |   Contact Us
Copyright Notices   |   Terms of Use   |   Privacy Statement